Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Two anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) have been approved for the treatment of patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer (NSCLC). Severe hepatotoxicity has been observed in several clinical studies. We aim to assess t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bing, Yuan, Maoxi, Sun, Yi, Cheng, Ziming, Zhang, Zaiyong, Hou, Shizheng, Wang, Xiangdong, Liu, Jingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823621/
https://www.ncbi.nlm.nih.gov/pubmed/29507704
http://dx.doi.org/10.18632/oncotarget.23840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823621/
https://www.ncbi.nlm.nih.gov/pubmed/29507704
http://dx.doi.org/10.18632/oncotarget.23840

Ejemplares similares